BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27858316)

  • 21. An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
    Luo J; Liu S; Leung S; Gru AA; Tao Y; Hoog J; Ho J; Davies SR; Allred DC; Salavaggione AL; Snider J; Mardis ER; Nielsen TO; Ellis MJ
    J Mol Diagn; 2017 Jan; 19(1):147-161. PubMed ID: 27993329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Cai H; Guo W; Zhang S; Li N; Wang X; Liu H; Chen R; Wang S; Guo Z; Li J
    Breast Cancer Res Treat; 2018 Jul; 170(2):271-277. PubMed ID: 29572677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.
    Figueroa JD; Yang H; Garcia-Closas M; Davis S; Meltzer P; Lissowska J; Horne HN; Sherman ME; Lee M
    Breast Cancer Res Treat; 2015 Apr; 150(2):457-466. PubMed ID: 25773928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genes and functions from breast cancer signatures.
    Huang S; Murphy L; Xu W
    BMC Cancer; 2018 Apr; 18(1):473. PubMed ID: 29699511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
    Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
    BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer.
    Liu D
    FEBS J; 2016 Aug; 283(16):3115-33. PubMed ID: 27376509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic role of progesterone receptor expression in a population-based analysis.
    Caldarella A; Barchielli A
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2505-2509. PubMed ID: 28889189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of a 92-probe signature in breast cancer.
    Akter S; Choi TG; Nguyen MN; Matondo A; Kim JH; Jo YH; Jo A; Shahid M; Jun DY; Yoo JY; Nguyen NN; Seo SW; Ali L; Lee JS; Yoon KS; Choe W; Kang I; Ha J; Kim J; Kim SS
    Oncotarget; 2015 Jun; 6(17):15662-80. PubMed ID: 25883221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.
    Ahmed W; Malik MFA; Saeed M; Haq F
    Mol Biol Rep; 2018 Dec; 45(6):2185-2192. PubMed ID: 30225582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
    Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
    Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
    J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
    Ma XM; Han YW; Zhang J; Cui WJ; Wang X
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
    Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
    Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.